InvestorsHub Logo
Followers 129
Posts 2150
Boards Moderated 1
Alias Born 12/27/2007

Re: None

Friday, 07/10/2020 6:44:43 AM

Friday, July 10, 2020 6:44:43 AM

Post# of 644762
GENX.V =MC $7 M /Selling COVID 19 TREATMENT =LIFETIME OPP ??

COMPLETELY undiscovered and very cheap stock with brutally upside...This stock which trading at 18 cents could run to $5 and much higher because of current Corona hype .. as an example Sona Nanotech (SONA.C) another canadian Corona gem explodes from 12 cents to $9 .This could be a MONSTER Pick for the coming days and weeks .GLTA


Genix Pharma (GENX.V)

Market Cap: C$9.7Million (= around US$ 7.1 Million)
Price 0.185


Genix Pharmaceuticals Corporation Enters into a Definitive Agreement to Acquire Global Rights to Flu-X(R)
https://finance.yahoo.com/news/genix-pharmaceuticals-corporation-enters-definitive-130000064.html

A Novel and Proprietary Anti-Viral, Anti-Flu and Common Colds Coronavirus(1) Spray

"We are truly excited about acquiring the global rights to Flu-X®. It was used safely and effectively in China during the SARS-CoV epidemic and has been shown to be effective against several coronaviruses1," stated Sina Pirooz, the Company's CEO. "Since there are striking similarities between the SARS and COVID-19 coronaviruses, we are encouraged about the potential of Flu-X® on COVID-19," added Mr. Pirooz

GENIX plans to commence global sales of Flu-X® immediately
and in Canada once regulatory approval


Genix Pharmaceuticals Corporation Completes Purchase of Rights to 30 Ophthalmic Generic Drugs and Product Dossiers
https://finance.yahoo.com/news/genix-pharmaceuticals-corporation-completes-purchase-090000198.html


Genix Acquires Exclusive Rights to SUCANON(R) and RENOCHLOR(R)
https://finance.yahoo.com/news/genix-acquires-exclusive-rights-sucanon-194200744.html

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.